Glenmark Pharmaceuticals Ltd.
•₹ 2,317.9-0.64%
2026-08-21
PROS
- Company is almost debt free
- Latest quarter profit grew 927.9% YoY, showing strong momentum
- Operating margins have improved to 13.2% from 6.8%
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 4.07x)
- Company has a consistent dividend-paying track record
- Company generates healthy free cash flow
CONS
- Company has a low return on equity of 1.8% over last 3 years
- Receivables are growing faster than sales - a possible quality concern
- Operating cash flow has been negative in recent years
- Recurring exceptional / one-off items are inflating headline profit
- Company has delivered a poor profit growth of 7.0% over past five years
- Stock is trading at 5.7x its book value
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
EDIT COLUMNS| S.No. | Name | CMP Rs. | P/E | Mar Cap Rs.Cr. | Div Yld % | NP Qtr Rs.Cr. | Qtr Profit Var % | Sales Qtr Rs.Cr. | Qtr Sales Var % | ROCE % | OPM % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | SUNPHARMA | 1898.00 | 37.65 | 455393.78 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| 2. | DIVISLAB | 8525.00 | 77.37 | 226311.96 | 0.35 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| 3. | TORNTPHARM | 5013.00 | 87.43 | 190678.41 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| 4. | CIPLA | 1416.00 | 33.94 | 114392.01 | 0.92 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| 5. | ZYDUSLIFE | 1105.00 | 24.42 | 110224.17 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| 6. | LUPIN | 2220.00 | 18.36 | 101506.15 | 0.81 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| 7. | MANKIND | 2391.00 | 48.34 | 98747.34 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| 8. | DRREDDY | 1171.00 | 30.33 | 97740.54 | 0.68 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| 9. | LAURUSLABS | 1807.00 | 89.30 | 97634.42 | 0.11 | 3620.70 | 2139.42 | 20263.10 | 1191.00 | 18.20 | 31.50 |
| 10. | AUROPHARMA | 1615.15 | 25.03 | 92932.16 | 0.25 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| 11. | BIOCON | 414.30 | 136.32 | 67518.23 | 0.12 | 136.80 | 53.36 | 4336.00 | 10.89 | 3.26 | 19.54 |
| 12. | GLENMARK | 2255.00 | 35.40 | 63641.66 | 0.11 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
Detailed Comparison with:
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2,998 | 3,161 | 2,460 | 3,016 | 3,223 | 3,400 | 3,302 | 3,220 | 3,059 | 6,004 | 3,888 | 3,760 | 4,018 | |
| 2,599 | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 | 3,008 | 3,441 | |
| Operating Profit | — | — | — | — | — | — | — | — | — | — | — | — | — |
| OPM % | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Income | 20 | 2 | 45 | 773 | 31 | 39 | 31 | 12 | 26 | 201 | 44 | 189 | 66 |
| Interest | 112 | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 | 41 | 43 | 54 |
| Depreciation | 142 | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 |
| 151 | -124 | -521 | 531 | 462 | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 | |
| Tax % | 75.12% | -44.99% | 13.77% | 333.34% | 26.41% | 24.99% | 23.73% | 45.04% | 50.86% | 36.90% | 24.49% | 22.29% | 24.96% |
| Net Profit | 0 | 0 | 0 | 0 | 340 | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 |
| 1 | -7 | -17 | -44 | 12 | 13 | 12 | 0 | 2 | 22 | 14 | 11 | 2 | |
| Equity Capital | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Equity Capital | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Jun 2023
- 2,998
- 2,599
- Operating Profit
- —
- OPM %
- —
- Other Income
- 20
- Interest
- 112
- Depreciation
- 142
- 151
- Tax %
- 75.12%
- Net Profit
- 0
- 1
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Sep 2023
- 3,161
- 2,745
- Operating Profit
- —
- OPM %
- —
- Other Income
- 2
- Interest
- 121
- Depreciation
- 141
- -124
- Tax %
- -44.99%
- Net Profit
- 0
- -7
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Dec 2023
- 2,460
- 2,715
- Operating Profit
- —
- OPM %
- —
- Other Income
- 45
- Interest
- 134
- Depreciation
- 147
- -521
- Tax %
- 13.77%
- Net Profit
- 0
- -17
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Mar 2024
- 3,016
- 2,559
- Operating Profit
- —
- OPM %
- —
- Other Income
- 773
- Interest
- 149
- Depreciation
- 151
- 531
- Tax %
- 333.34%
- Net Profit
- 0
- -44
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Jun 2024
- 3,223
- 2,656
- Operating Profit
- —
- OPM %
- —
- Other Income
- 31
- Interest
- 40
- Depreciation
- 118
- 462
- Tax %
- 26.41%
- Net Profit
- 340
- 12
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Sep 2024
- 3,400
- 2,832
- Operating Profit
- —
- OPM %
- —
- Other Income
- 39
- Interest
- 48
- Depreciation
- 120
- 473
- Tax %
- 24.99%
- Net Profit
- 354
- 13
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Dec 2024
- 3,302
- 2,787
- Operating Profit
- —
- OPM %
- —
- Other Income
- 31
- Interest
- 52
- Depreciation
- 123
- 456
- Tax %
- 23.73%
- Net Profit
- 348
- 12
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Mar 2025
- 3,220
- 2,695
- Operating Profit
- —
- OPM %
- —
- Other Income
- 12
- Interest
- 67
- Depreciation
- 125
- 8
- Tax %
- 45.04%
- Net Profit
- 4
- 0
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Jun 2025
- 3,059
- 2,684
- Operating Profit
- —
- OPM %
- —
- Other Income
- 26
- Interest
- 58
- Depreciation
- 130
- 96
- Tax %
- 50.86%
- Net Profit
- 47
- 2
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Sep 2025
- 6,004
- 3,687
- Operating Profit
- —
- OPM %
- —
- Other Income
- 201
- Interest
- 66
- Depreciation
- 141
- 967
- Tax %
- 36.90%
- Net Profit
- 610
- 22
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Dec 2025
- 3,888
- 3,031
- Operating Profit
- —
- OPM %
- —
- Other Income
- 44
- Interest
- 41
- Depreciation
- 154
- 534
- Tax %
- 24.49%
- Net Profit
- 403
- 14
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Mar 2026
- 3,760
- 3,008
- Operating Profit
- —
- OPM %
- —
- Other Income
- 189
- Interest
- 43
- Depreciation
- 148
- 388
- Tax %
- 22.29%
- Net Profit
- 301
- 11
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Jun 2026
- 4,018
- 3,441
- Operating Profit
- —
- OPM %
- —
- Other Income
- 66
- Interest
- 54
- Depreciation
- 173
- 643
- Tax %
- 24.96%
- Net Profit
- 483
- 2
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 28
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 9,186 | 9,103 | 9,865 | 10,641 | 10,944 | 12,305 | 11,583 | 11,813 | 13,322 | 16,983 | 17,671 | |
| 7,149 | 7,488 | 8,280 | 8,943 | 8,860 | 9,985 | 9,948 | 10,618 | 10,970 | 12,410 | 13,167 | |
| Operating Profit | 2,074 | 1,707 | 1,794 | 1,858 | 2,135 | 2,487 | 1,924 | 2,035 | 2,465 | 5,033 | — |
| OPM % | 23 | 19 | 18 | 17 | 20 | 20 | 17 | 17 | 19 | 30 | — |
| Other Income | 37 | 91 | 208 | 160 | 50 | 167 | 289 | 840 | 114 | 461 | 500 |
| Interest | 237 | 286 | 335 | 377 | 353 | 298 | 349 | 516 | 207 | 209 | 204 |
| Depreciation | 264 | 302 | 326 | 417 | 444 | 487 | 569 | 582 | 486 | 573 | 617 |
| 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 240 | 36 | 1,399 | 1,985 | 2,533 | |
| Tax % | 26 | 28 | 29 | 29 | 30 | 31 | 137 | 5,117 | 25 | 31 | 29 |
| Net Profit | 1,109 | 804 | 925 | 776 | 970 | 994 | -90 | -1,831 | 1,047 | 1,362 | 1,798 |
| EPS | 39 | 28 | 33 | 28 | 34 | 33 | 11 | -53 | 37 | 48 | — |
| Dividend Payout % | 5 | 7 | 6 | 9 | 7 | 7 | 24 | -5 | 7 | 5 | — |
| Minority Interest | 0 | -0 | -0 | -0 | -0 | -52 | -80 | -68 | -0 | -0 | -0 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 39 | 28 | 33 | 28 | 34 | 33 | 11 | -53 | 37 | 48 | — |
| Minority Interest | 0 | -0 | -0 | -0 | -0 | -52 | -80 | -68 | -0 | -0 | -0 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 39 | 28 | 33 | 28 | 34 | 33 | 11 | -53 | 37 | 48 | — |
Mar 2017
- 9,186
- 7,149
- Operating Profit
- 2,074
- OPM %
- 23
- Other Income
- 37
- Interest
- 237
- Depreciation
- 264
- 1,491
- Tax %
- 26
- Net Profit
- 1,109
- EPS
- 39
- Dividend Payout %
- 5
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 39
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 39
Mar 2018
- 9,103
- 7,488
- Operating Profit
- 1,707
- OPM %
- 19
- Other Income
- 91
- Interest
- 286
- Depreciation
- 302
- 1,119
- Tax %
- 28
- Net Profit
- 804
- EPS
- 28
- Dividend Payout %
- 7
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 28
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 28
Mar 2019
- 9,865
- 8,280
- Operating Profit
- 1,794
- OPM %
- 18
- Other Income
- 208
- Interest
- 335
- Depreciation
- 326
- 1,301
- Tax %
- 29
- Net Profit
- 925
- EPS
- 33
- Dividend Payout %
- 6
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 33
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 33
Mar 2020
- 10,641
- 8,943
- Operating Profit
- 1,858
- OPM %
- 17
- Other Income
- 160
- Interest
- 377
- Depreciation
- 417
- 1,096
- Tax %
- 29
- Net Profit
- 776
- EPS
- 28
- Dividend Payout %
- 9
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 28
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 28
Mar 2021
- 10,944
- 8,860
- Operating Profit
- 2,135
- OPM %
- 20
- Other Income
- 50
- Interest
- 353
- Depreciation
- 444
- 1,382
- Tax %
- 30
- Net Profit
- 970
- EPS
- 34
- Dividend Payout %
- 7
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 34
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 34
Mar 2022
- 12,305
- 9,985
- Operating Profit
- 2,487
- OPM %
- 20
- Other Income
- 167
- Interest
- 298
- Depreciation
- 487
- 1,441
- Tax %
- 31
- Net Profit
- 994
- EPS
- 33
- Dividend Payout %
- 7
- Minority Interest
- -52
- Share of Associates
- 0
- Adjusted EPS
- 33
- Minority Interest
- -52
- Share of Associates
- 0
- Adjusted EPS
- 33
Mar 2023
- 11,583
- 9,948
- Operating Profit
- 1,924
- OPM %
- 17
- Other Income
- 289
- Interest
- 349
- Depreciation
- 569
- 240
- Tax %
- 137
- Net Profit
- -90
- EPS
- 11
- Dividend Payout %
- 24
- Minority Interest
- -80
- Share of Associates
- 0
- Adjusted EPS
- 11
- Minority Interest
- -80
- Share of Associates
- 0
- Adjusted EPS
- 11
Mar 2024
- 11,813
- 10,618
- Operating Profit
- 2,035
- OPM %
- 17
- Other Income
- 840
- Interest
- 516
- Depreciation
- 582
- 36
- Tax %
- 5,117
- Net Profit
- -1,831
- EPS
- -53
- Dividend Payout %
- -5
- Minority Interest
- -68
- Share of Associates
- 0
- Adjusted EPS
- -53
- Minority Interest
- -68
- Share of Associates
- 0
- Adjusted EPS
- -53
Mar 2025
- 13,322
- 10,970
- Operating Profit
- 2,465
- OPM %
- 19
- Other Income
- 114
- Interest
- 207
- Depreciation
- 486
- 1,399
- Tax %
- 25
- Net Profit
- 1,047
- EPS
- 37
- Dividend Payout %
- 7
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 37
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 37
Mar 2026
- 16,983
- 12,410
- Operating Profit
- 5,033
- OPM %
- 30
- Other Income
- 461
- Interest
- 209
- Depreciation
- 573
- 1,985
- Tax %
- 31
- Net Profit
- 1,362
- EPS
- 48
- Dividend Payout %
- 5
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 48
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 48
TTM
- 17,671
- 13,167
- Operating Profit
- —
- OPM %
- —
- Other Income
- 500
- Interest
- 204
- Depreciation
- 617
- 2,533
- Tax %
- 29
- Net Profit
- 1,798
- EPS
- —
- Dividend Payout %
- —
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- —
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- —
COMPOUNDED SALES GROWTH
- 10 Years:
- 8%
- 5 Years:
- 9%
- 3 Years:
- 14%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 6%
- 5 Years:
- 7%
- 3 Years:
- 66%
STOCK PRICE CAGR
- 10 Years:
- 11%
- 5 Years:
- 34%
- 3 Years:
- 44%
- 1 Year:
- 21%
RETURN ON EQUITY
- 10 Years:
- 11%
- 5 Years:
- 3%
- 3 Years:
- 2%
- Last Year:
- 14%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| LIABILITIES | - | - | - | - | - | - | - | - | - | - |
| Equity Capital | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| 4,463 | 5,125 | 5,566 | 6,029 | 7,015 | 9,042 | 9,428 | 7,801 | 8,812 | 10,450 | |
| 187 | 295 | 303 | 443 | 513 | 370 | 350 | 833 | 1,681 | 0 | |
| Trade Payables | 1,743 | 1,870 | 2,221 | 2,126 | 2,238 | 2,289 | 2,000 | 2,536 | 3,051 | 3,744 |
| 4,031 | 3,957 | 3,787 | 4,604 | 4,275 | 3,668 | 5,759 | 2,110 | 1,352 | 4,439 | |
| Total Liabilities | 10,453 | 11,275 | 11,906 | 13,229 | 14,069 | 15,397 | 17,566 | 13,309 | 14,925 | 18,661 |
| ASSETS | - | - | - | - | - | - | - | - | - | - |
| 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 5,422 | 4,210 | 4,487 | 5,915 | |
| Capital Work in Progress | 630 | 993 | 1,234 | 1,091 | 1,218 | 921 | 1,066 | 419 | 542 | 428 |
| 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 56 | 42 | |
| 2,139 | 2,031 | 2,252 | 2,136 | 2,277 | 2,500 | 2,374 | 2,513 | 3,029 | 3,431 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,858 | 3,342 | 4,963 | |
| Cash & Bank | 1,058 | 1,235 | 938 | 1,111 | 1,139 | 1,412 | 1,160 | 1,659 | 1,705 | 1,176 |
| 3,856 | 3,972 | 3,782 | 3,838 | 4,282 | 4,628 | 7,500 | 1,859 | 1,765 | 2,706 | |
| Total Assets | 10,453 | 11,275 | 11,906 | 13,229 | 14,069 | 15,397 | 17,566 | 13,309 | 14,925 | 18,661 |
| Total Debt | 4,724 | 4,639 | 4,449 | 4,869 | 4,687 | 3,670 | 4,348 | 991 | 2,194 | 0 |
| Net Working Capital | 4,172 | 3,701 | 2,676 | 2,678 | 3,159 | 3,593 | 3,877 | 1,609 | 3,328 | 4,923 |
| Contingent Liabilities | 37 | 47 | 74 | 271 | 384 | 361 | 337 | 1,063 | 800 | 788 |
| Book Value per Share | 159.16 | 182.62 | 198.27 | 214.65 | 249.60 | 321.45 | 335.13 | 277.46 | 313.28 | 371.30 |
| Face Value | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Total Debt | 4,724 | 4,639 | 4,449 | 4,869 | 4,687 | 3,670 | 4,348 | 991 | 2,194 | 0 |
| Net Working Capital | 4,172 | 3,701 | 2,676 | 2,678 | 3,159 | 3,593 | 3,877 | 1,609 | 3,328 | 4,923 |
| Contingent Liabilities | 37 | 47 | 74 | 271 | 384 | 361 | 337 | 1,063 | 800 | 788 |
| Book Value per Share | 159.16 | 182.62 | 198.27 | 214.65 | 249.60 | 321.45 | 335.13 | 277.46 | 313.28 | 371.30 |
| Face Value | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Mar 2017
- Equity Capital
- 28
- 4,463
- 187
- Trade Payables
- 1,743
- 4,031
- Total Liabilities
- 10,453
- 2,755
- Capital Work in Progress
- 630
- 16
- 2,139
- 0
- Cash & Bank
- 1,058
- 3,856
- Total Assets
- 10,453
- Total Debt
- 4,724
- Net Working Capital
- 4,172
- Contingent Liabilities
- 37
- Book Value per Share
- 159.16
- Face Value
- 1.00
- Total Debt
- 4,724
- Net Working Capital
- 4,172
- Contingent Liabilities
- 37
- Book Value per Share
- 159.16
- Face Value
- 1.00
Mar 2018
- Equity Capital
- 28
- 5,125
- 295
- Trade Payables
- 1,870
- 3,957
- Total Liabilities
- 11,275
- 3,030
- Capital Work in Progress
- 993
- 15
- 2,031
- 0
- Cash & Bank
- 1,235
- 3,972
- Total Assets
- 11,275
- Total Debt
- 4,639
- Net Working Capital
- 3,701
- Contingent Liabilities
- 47
- Book Value per Share
- 182.62
- Face Value
- 1.00
- Total Debt
- 4,639
- Net Working Capital
- 3,701
- Contingent Liabilities
- 47
- Book Value per Share
- 182.62
- Face Value
- 1.00
Mar 2019
- Equity Capital
- 28
- 5,566
- 303
- Trade Payables
- 2,221
- 3,787
- Total Liabilities
- 11,906
- 3,670
- Capital Work in Progress
- 1,234
- 30
- 2,252
- 0
- Cash & Bank
- 938
- 3,782
- Total Assets
- 11,906
- Total Debt
- 4,449
- Net Working Capital
- 2,676
- Contingent Liabilities
- 74
- Book Value per Share
- 198.27
- Face Value
- 1.00
- Total Debt
- 4,449
- Net Working Capital
- 2,676
- Contingent Liabilities
- 74
- Book Value per Share
- 198.27
- Face Value
- 1.00
Mar 2020
- Equity Capital
- 28
- 6,029
- 443
- Trade Payables
- 2,126
- 4,604
- Total Liabilities
- 13,229
- 5,029
- Capital Work in Progress
- 1,091
- 25
- 2,136
- 0
- Cash & Bank
- 1,111
- 3,838
- Total Assets
- 13,229
- Total Debt
- 4,869
- Net Working Capital
- 2,678
- Contingent Liabilities
- 271
- Book Value per Share
- 214.65
- Face Value
- 1.00
- Total Debt
- 4,869
- Net Working Capital
- 2,678
- Contingent Liabilities
- 271
- Book Value per Share
- 214.65
- Face Value
- 1.00
Mar 2021
- Equity Capital
- 28
- 7,015
- 513
- Trade Payables
- 2,238
- 4,275
- Total Liabilities
- 14,069
- 5,129
- Capital Work in Progress
- 1,218
- 25
- 2,277
- 0
- Cash & Bank
- 1,139
- 4,282
- Total Assets
- 14,069
- Total Debt
- 4,687
- Net Working Capital
- 3,159
- Contingent Liabilities
- 384
- Book Value per Share
- 249.60
- Face Value
- 1.00
- Total Debt
- 4,687
- Net Working Capital
- 3,159
- Contingent Liabilities
- 384
- Book Value per Share
- 249.60
- Face Value
- 1.00
Mar 2022
- Equity Capital
- 28
- 9,042
- 370
- Trade Payables
- 2,289
- 3,668
- Total Liabilities
- 15,397
- 5,887
- Capital Work in Progress
- 921
- 50
- 2,500
- 0
- Cash & Bank
- 1,412
- 4,628
- Total Assets
- 15,397
- Total Debt
- 3,670
- Net Working Capital
- 3,593
- Contingent Liabilities
- 361
- Book Value per Share
- 321.45
- Face Value
- 1.00
- Total Debt
- 3,670
- Net Working Capital
- 3,593
- Contingent Liabilities
- 361
- Book Value per Share
- 321.45
- Face Value
- 1.00
Mar 2023
- Equity Capital
- 28
- 9,428
- 350
- Trade Payables
- 2,000
- 5,759
- Total Liabilities
- 17,566
- 5,422
- Capital Work in Progress
- 1,066
- 45
- 2,374
- 0
- Cash & Bank
- 1,160
- 7,500
- Total Assets
- 17,566
- Total Debt
- 4,348
- Net Working Capital
- 3,877
- Contingent Liabilities
- 337
- Book Value per Share
- 335.13
- Face Value
- 1.00
- Total Debt
- 4,348
- Net Working Capital
- 3,877
- Contingent Liabilities
- 337
- Book Value per Share
- 335.13
- Face Value
- 1.00
Mar 2024
- Equity Capital
- 28
- 7,801
- 833
- Trade Payables
- 2,536
- 2,110
- Total Liabilities
- 13,309
- 4,210
- Capital Work in Progress
- 419
- 790
- 2,513
- 1,858
- Cash & Bank
- 1,659
- 1,859
- Total Assets
- 13,309
- Total Debt
- 991
- Net Working Capital
- 1,609
- Contingent Liabilities
- 1,063
- Book Value per Share
- 277.46
- Face Value
- 1.00
- Total Debt
- 991
- Net Working Capital
- 1,609
- Contingent Liabilities
- 1,063
- Book Value per Share
- 277.46
- Face Value
- 1.00
Mar 2025
- Equity Capital
- 28
- 8,812
- 1,681
- Trade Payables
- 3,051
- 1,352
- Total Liabilities
- 14,925
- 4,487
- Capital Work in Progress
- 542
- 56
- 3,029
- 3,342
- Cash & Bank
- 1,705
- 1,765
- Total Assets
- 14,925
- Total Debt
- 2,194
- Net Working Capital
- 3,328
- Contingent Liabilities
- 800
- Book Value per Share
- 313.28
- Face Value
- 1.00
- Total Debt
- 2,194
- Net Working Capital
- 3,328
- Contingent Liabilities
- 800
- Book Value per Share
- 313.28
- Face Value
- 1.00
Mar 2026
- Equity Capital
- 28
- 10,450
- 0
- Trade Payables
- 3,744
- 4,439
- Total Liabilities
- 18,661
- 5,915
- Capital Work in Progress
- 428
- 42
- 3,431
- 4,963
- Cash & Bank
- 1,176
- 2,706
- Total Assets
- 18,661
- Total Debt
- 0
- Net Working Capital
- 4,923
- Contingent Liabilities
- 788
- Book Value per Share
- 371.30
- Face Value
- 1.00
- Total Debt
- 0
- Net Working Capital
- 4,923
- Contingent Liabilities
- 788
- Book Value per Share
- 371.30
- Face Value
- 1.00
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | 625 | -265 | -828 | 3,445 | |
| Cash from Investing | -712 | -1,013 | -699 | -784 | -675 | -333 | -528 | 4,561 | 2 | -1,283 |
| Cash from Financing | 543 | -468 | -739 | -445 | -442 | -520 | -77 | -3,906 | 787 | -2,709 |
| 488 | 166 | -114 | 164 | 14 | 255 | 19 | 389 | -38 | -547 | |
| Free Cash Flow | 56 | 686 | -76 | -206 | 542 | -77 | 335 | -265 | -1,696 | 1,852 |
| OCF / Net Profit | 0.59 | 2.05 | 1.43 | 1.79 | 1.17 | 1.12 | -6.98 | 0.14 | -0.79 | 2.53 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 1,002 | 869 | 518 | 328 | -1,161 | 149 |
| OCF / Net Profit | 0.59 | 2.05 | 1.43 | 1.79 | 1.17 | 1.12 | -6.98 | 0.14 | -0.79 | 2.53 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 1,002 | 869 | 518 | 328 | -1,161 | 149 |
Mar 2017
- 657
- Cash from Investing
- -712
- Cash from Financing
- 543
- 488
- Free Cash Flow
- 56
- OCF / Net Profit
- 0.59
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 0.59
- Cumulative 5-Year FCF
- 0
Mar 2018
- 1,648
- Cash from Investing
- -1,013
- Cash from Financing
- -468
- 166
- Free Cash Flow
- 686
- OCF / Net Profit
- 2.05
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 2.05
- Cumulative 5-Year FCF
- 0
Mar 2019
- 1,324
- Cash from Investing
- -699
- Cash from Financing
- -739
- -114
- Free Cash Flow
- -76
- OCF / Net Profit
- 1.43
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.43
- Cumulative 5-Year FCF
- 0
Mar 2020
- 1,392
- Cash from Investing
- -784
- Cash from Financing
- -445
- 164
- Free Cash Flow
- -206
- OCF / Net Profit
- 1.79
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.79
- Cumulative 5-Year FCF
- 0
Mar 2021
- 1,131
- Cash from Investing
- -675
- Cash from Financing
- -442
- 14
- Free Cash Flow
- 542
- OCF / Net Profit
- 1.17
- Cumulative 5-Year FCF
- 1,002
- OCF / Net Profit
- 1.17
- Cumulative 5-Year FCF
- 1,002
Mar 2022
- 1,109
- Cash from Investing
- -333
- Cash from Financing
- -520
- 255
- Free Cash Flow
- -77
- OCF / Net Profit
- 1.12
- Cumulative 5-Year FCF
- 869
- OCF / Net Profit
- 1.12
- Cumulative 5-Year FCF
- 869
Mar 2023
- 625
- Cash from Investing
- -528
- Cash from Financing
- -77
- 19
- Free Cash Flow
- 335
- OCF / Net Profit
- -6.98
- Cumulative 5-Year FCF
- 518
- OCF / Net Profit
- -6.98
- Cumulative 5-Year FCF
- 518
Mar 2024
- -265
- Cash from Investing
- 4,561
- Cash from Financing
- -3,906
- 389
- Free Cash Flow
- -265
- OCF / Net Profit
- 0.14
- Cumulative 5-Year FCF
- 328
- OCF / Net Profit
- 0.14
- Cumulative 5-Year FCF
- 328
Mar 2025
- -828
- Cash from Investing
- 2
- Cash from Financing
- 787
- -38
- Free Cash Flow
- -1,696
- OCF / Net Profit
- -0.79
- Cumulative 5-Year FCF
- -1,161
- OCF / Net Profit
- -0.79
- Cumulative 5-Year FCF
- -1,161
Mar 2026
- 3,445
- Cash from Investing
- -1,283
- Cash from Financing
- -2,709
- -547
- Free Cash Flow
- 1,852
- OCF / Net Profit
- 2.53
- Cumulative 5-Year FCF
- 149
- OCF / Net Profit
- 2.53
- Cumulative 5-Year FCF
- 149
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| PER SHARE | - | - | - | - | - | - | - | - | - | - |
| EPS (₹) | 39.30 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.21 | 37.11 | 48.26 |
| Book Value (₹) | 159.16 | 182.62 | 198.27 | 214.65 | 249.60 | 321.45 | 335.13 | 277.46 | 313.28 | 371.30 |
| Dividend per Share (₹) | 2.00 | 2.00 | 2.00 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 |
| Cash EPS (₹) | 48.66 | 39.19 | 44.33 | 42.28 | 50.10 | 52.46 | 17.00 | -44.26 | 54.33 | 68.58 |
| PROFITABILITY | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 22.58% | 18.75% | 8.52% | 7.83% | 8.46% | 8.94% | 6.82% | 4.31% | 8.19% | 13.21% |
| Net Margin % | 12.07% | 8.83% | 4.39% | 3.27% | 3.84% | 3.57% | -0.32% | -6.61% | 3.65% | 3.93% |
| ROE % | 27.31% | 16.67% | 17.21% | 13.32% | 14.81% | 12.33% | -0.97% | -21.18% | 12.56% | 14.10% |
| ROCE % | 20.54% | 14.77% | 16.47% | 14.04% | 15.30% | 14.19% | 4.43% | 4.88% | 16.16% | 20.35% |
| 11.33% | 7.40% | 7.98% | 6.17% | 7.11% | 6.74% | -0.54% | -11.86% | 7.42% | 8.11% | |
| EFFICIENCY | - | - | - | - | - | - | - | - | - | - |
| Debtor Days | 97 | 95 | 39 | 35 | 36 | 37 | 44 | 36 | 33 | 44 |
| Inventory Days | 74 | 84 | 37 | 34 | 32 | 31 | 32 | 32 | 35 | 34 |
| Payable Days | 263 | 222 | 227 | 219 | 220 | 192 | 186 | 190 | 238 | 265 |
| -93 | -43 | -150 | -150 | -152 | -123 | -111 | -122 | -170 | -187 | |
| FINANCIAL HEALTH | - | - | - | - | - | - | - | - | - | - |
| Debt to Equity (x) | 1.05x | 0.90x | 0.80x | 0.80x | 0.67x | 0.40x | 0.46x | 0.13x | 0.25x | 0.00x |
| Interest Coverage (x) | 7.28x | 4.92x | 4.89x | 3.90x | 4.92x | 5.83x | 1.69x | 1.07x | 7.76x | 10.51x |
| 2.54x | 2.13x | 1.67x | 1.65x | 1.75x | 1.77x | 1.85x | 1.28x | 1.56x | 1.77x | |
| GROWTH | - | - | - | - | - | - | - | - | - | - |
| Revenue Growth % | 20.08% | -0.90% | 8.38% | 7.86% | 2.85% | 12.44% | -5.86% | 1.98% | 12.77% | 27.48% |
| Operating Profit Growth % | 42.34% | -17.71% | 5.11% | 3.55% | 14.91% | 16.51% | -22.64% | 5.79% | 21.12% | 104.17% |
| Net Profit Growth % | 49.22% | -27.50% | 15.07% | -16.11% | 25.02% | 2.43% | -109.01% | -1944.25% | 157.19% | 30.06% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -605.16% | 169.73% | 30.06% | |
| VALUATION | - | - | - | - | - | - | - | - | - | - |
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 41.50x | 44.21x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 3.45x | 4.92x | 5.75x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.26% | 0.16% | 0.12% |
| 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 12.95x | 17.83x | 11.73x |
Mar 2017
- EPS (₹)
- 39.30
- Book Value (₹)
- 159.16
- Dividend per Share (₹)
- 2.00
- Cash EPS (₹)
- 48.66
- Operating Margin %
- 22.58%
- Net Margin %
- 12.07%
- ROE %
- 27.31%
- ROCE %
- 20.54%
- 11.33%
- Debtor Days
- 97
- Inventory Days
- 74
- Payable Days
- 263
- -93
- Debt to Equity (x)
- 1.05x
- Interest Coverage (x)
- 7.28x
- 2.54x
- Revenue Growth %
- 20.08%
- Operating Profit Growth %
- 42.34%
- Net Profit Growth %
- 49.22%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2018
- EPS (₹)
- 28.49
- Book Value (₹)
- 182.62
- Dividend per Share (₹)
- 2.00
- Cash EPS (₹)
- 39.19
- Operating Margin %
- 18.75%
- Net Margin %
- 8.83%
- ROE %
- 16.67%
- ROCE %
- 14.77%
- 7.40%
- Debtor Days
- 95
- Inventory Days
- 84
- Payable Days
- 222
- -43
- Debt to Equity (x)
- 0.90x
- Interest Coverage (x)
- 4.92x
- 2.13x
- Revenue Growth %
- -0.90%
- Operating Profit Growth %
- -17.71%
- Net Profit Growth %
- -27.50%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2019
- EPS (₹)
- 32.78
- Book Value (₹)
- 198.27
- Dividend per Share (₹)
- 2.00
- Cash EPS (₹)
- 44.33
- Operating Margin %
- 8.52%
- Net Margin %
- 4.39%
- ROE %
- 17.21%
- ROCE %
- 16.47%
- 7.98%
- Debtor Days
- 39
- Inventory Days
- 37
- Payable Days
- 227
- -150
- Debt to Equity (x)
- 0.80x
- Interest Coverage (x)
- 4.89x
- 1.67x
- Revenue Growth %
- 8.38%
- Operating Profit Growth %
- 5.11%
- Net Profit Growth %
- 15.07%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2020
- EPS (₹)
- 27.50
- Book Value (₹)
- 214.65
- Dividend per Share (₹)
- 2.50
- Cash EPS (₹)
- 42.28
- Operating Margin %
- 7.83%
- Net Margin %
- 3.27%
- ROE %
- 13.32%
- ROCE %
- 14.04%
- 6.17%
- Debtor Days
- 35
- Inventory Days
- 34
- Payable Days
- 219
- -150
- Debt to Equity (x)
- 0.80x
- Interest Coverage (x)
- 3.90x
- 1.65x
- Revenue Growth %
- 7.86%
- Operating Profit Growth %
- 3.55%
- Net Profit Growth %
- -16.11%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2021
- EPS (₹)
- 34.38
- Book Value (₹)
- 249.60
- Dividend per Share (₹)
- 2.50
- Cash EPS (₹)
- 50.10
- Operating Margin %
- 8.46%
- Net Margin %
- 3.84%
- ROE %
- 14.81%
- ROCE %
- 15.30%
- 7.11%
- Debtor Days
- 36
- Inventory Days
- 32
- Payable Days
- 220
- -152
- Debt to Equity (x)
- 0.67x
- Interest Coverage (x)
- 4.92x
- 1.75x
- Revenue Growth %
- 2.85%
- Operating Profit Growth %
- 14.91%
- Net Profit Growth %
- 25.02%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2022
- EPS (₹)
- 33.37
- Book Value (₹)
- 321.45
- Dividend per Share (₹)
- 2.50
- Cash EPS (₹)
- 52.46
- Operating Margin %
- 8.94%
- Net Margin %
- 3.57%
- ROE %
- 12.33%
- ROCE %
- 14.19%
- 6.74%
- Debtor Days
- 37
- Inventory Days
- 31
- Payable Days
- 192
- -123
- Debt to Equity (x)
- 0.40x
- Interest Coverage (x)
- 5.83x
- 1.77x
- Revenue Growth %
- 12.44%
- Operating Profit Growth %
- 16.51%
- Net Profit Growth %
- 2.43%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2023
- EPS (₹)
- 10.53
- Book Value (₹)
- 335.13
- Dividend per Share (₹)
- 2.50
- Cash EPS (₹)
- 17.00
- Operating Margin %
- 6.82%
- Net Margin %
- -0.32%
- ROE %
- -0.97%
- ROCE %
- 4.43%
- -0.54%
- Debtor Days
- 44
- Inventory Days
- 32
- Payable Days
- 186
- -111
- Debt to Equity (x)
- 0.46x
- Interest Coverage (x)
- 1.69x
- 1.85x
- Revenue Growth %
- -5.86%
- Operating Profit Growth %
- -22.64%
- Net Profit Growth %
- -109.01%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2024
- EPS (₹)
- -53.21
- Book Value (₹)
- 277.46
- Dividend per Share (₹)
- 2.50
- Cash EPS (₹)
- -44.26
- Operating Margin %
- 4.31%
- Net Margin %
- -6.61%
- ROE %
- -21.18%
- ROCE %
- 4.88%
- -11.86%
- Debtor Days
- 36
- Inventory Days
- 32
- Payable Days
- 190
- -122
- Debt to Equity (x)
- 0.13x
- Interest Coverage (x)
- 1.07x
- 1.28x
- Revenue Growth %
- 1.98%
- Operating Profit Growth %
- 5.79%
- Net Profit Growth %
- -1944.25%
- -605.16%
- P/E (x)
- 0.00x
- P/B (x)
- 3.45x
- Dividend Yield %
- 0.26%
- 12.95x
Mar 2025
- EPS (₹)
- 37.11
- Book Value (₹)
- 313.28
- Dividend per Share (₹)
- 2.50
- Cash EPS (₹)
- 54.33
- Operating Margin %
- 8.19%
- Net Margin %
- 3.65%
- ROE %
- 12.56%
- ROCE %
- 16.16%
- 7.42%
- Debtor Days
- 33
- Inventory Days
- 35
- Payable Days
- 238
- -170
- Debt to Equity (x)
- 0.25x
- Interest Coverage (x)
- 7.76x
- 1.56x
- Revenue Growth %
- 12.77%
- Operating Profit Growth %
- 21.12%
- Net Profit Growth %
- 157.19%
- 169.73%
- P/E (x)
- 41.50x
- P/B (x)
- 4.92x
- Dividend Yield %
- 0.16%
- 17.83x
Mar 2026
- EPS (₹)
- 48.26
- Book Value (₹)
- 371.30
- Dividend per Share (₹)
- 2.50
- Cash EPS (₹)
- 68.58
- Operating Margin %
- 13.21%
- Net Margin %
- 3.93%
- ROE %
- 14.10%
- ROCE %
- 20.35%
- 8.11%
- Debtor Days
- 44
- Inventory Days
- 34
- Payable Days
- 265
- -187
- Debt to Equity (x)
- 0.00x
- Interest Coverage (x)
- 10.51x
- 1.77x
- Revenue Growth %
- 27.48%
- Operating Profit Growth %
- 104.17%
- Net Profit Growth %
- 30.06%
- 30.06%
- P/E (x)
- 44.21x
- P/B (x)
- 5.75x
- Dividend Yield %
- 0.12%
- 11.73x
Documents
Announcements
- Press Release
2026-08-20 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 20, 2026, titled "Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray".
- Copy of Newspaper Publication
2026-08-15 - Glenmark Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Annual Reports
Credit Ratings
- Credit Rating
2025-09-19 - Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating
- Credit Rating- Revision
2025-07-23 - Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating- Revision
Concalls
Aug 2026
Jul 2026
Jun 2026